The Zacks Analyst Blog Highlights: CVS Health, Marriott, Enbridge, MetLife And Aon

For Immediate Release

Chicago, IL – August 10, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeCVS Health (NYSE: (NYSE:CVS) – Free Report), Marriott (NASDAQ: (NASDAQ:MAR) – Free Report), Enbridge (NYSE: (NYSE:ENB) – Free Report), MetLife (NYSE: (NYSE:MET) – Free Report) and Aon (NYSE: (NYSE:AON) – Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Top Stock Reports for CVS Health, Marriott & Enbridge

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including CVS Health (NYSE:CVS – Free Report), Marriott (NASDAQ:MAR – Free Report) and Enbridge (NYSE:ENB – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

CVS Health shares have outperformed the Zacks categorized Drug Stores industry year to date losing -0.4% vs. -4.4%. CVS Health posted better-than-expected second-quarter 2017 with both adjusted EPS and revenues beating expectations. Year-over-year top line growth was driven by a strong Pharmacy Services segment, benefiting from the upside in the Specialty Pharmacy.

The company’s strong PBM selling season is a major positive. However, poor year-over-year Retail/LTC numbers along with margin debacle resulted in a dull earnings performance by the company in the quarter. Despite an unimpressive bottom-line scenario the company has raised the lower-end of its earnings outlook for 2017 raising investors optimism. The Zacks analyst thinks the Omnicare and Target Pharmacy buyouts should drive enterprise value significantly in the days ahead.

(You canread the full research report on CVS Health here >>>).

Shares of Marriott have outperformed the Zacks Hotels industry in the year-to-date period (the stock is up +25.7% vs. +3.3% gain for the industry). Marriott’s second-quarter 2017 earnings beat expectations and increased year over year. Notably, with the purchase of Starwood, Marriott became the world's largest hotel company. In fact, the acquisition is likely to result in a bigger brand with increased scale and a robust development pipeline in the long run.

The Zacks analyst likes Marriott’s rising North-American business, sizeable international exposure and attractive brand-position. Further, its investments in technology for hotel bookings will improve guest experience, which in turn should boost occupancy. Yet lingering political uncertainties in key international markets, oversupply in some regions and currency headwinds might continue to limit revenue growth. Integration risks linked to Starwood purchase is an added concern.

(You can read the full research report on Marriott here >>>).

Enbridge’s shares have declined -1.9% over the last one year, significantly underperforming the Zacks Oil & Gas Production industry’s gain of +5.7% during the aforesaid period. The company has the longest and most sophisticated crude and liquids pipeline system in the world that spreads over 17,511 miles.

The Zacks analyst likes the merger with Spectra Energy (F:SEP) as it has made Enbridge the largest energy infrastructure company in North America in terms of enterprise value. Also, the transaction has given Enbridge the industry’s largest backlog of growth projects, worth around C$75 billion. The company believes that this huge backlog will help it to grow its dividend by 10–12% annually from 2018 to 2024.

However, the company’s substantial debt load is a matter of concern. Also, during second-quarter 2017, Enbridge reported lower-than-expected results owing to higher operating expenses and accelerated maintenance work at the upstream operations of customers.

(You can read the full research report on Enbridge here >>>).

Other noteworthy reports we are featuring today include MetLife (NYSE:MET – Free Report) and Aon (NYSE:AON – Free Report).

3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...

By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early.See Zacks' Top 3 Stocks to Ride This Space >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Get the full Report on CVS - FREE

Get the full Report on MAR - FREE

Get the full Report on ENB - FREE

Get the full Report on MET - FREE

Get the full Report on AON - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.